Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein

Ridker, Paul M.; MacFadyen, Jean; Cressman, Michael D.; Glynn, Robert J.

doi:10.1016/j.jacc.2010.01.020

Cited by 184 publications

(52 citation statements)

References 18 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This argument is in keeping with issues raised already in the AURORA study, regarding the differences in cardiovascular effects of statins between patients on HD and patients with less advanced chronic kidney disease. It is interesting that most lately, a secondary analysis of the JU-PITER study has shown that rosuvastatin treatment had significant beneficial cardiovascular effects in patients with mild renal disease, increased CRP and no hyperlipidemia 29) . Therefore, we consider that the results of our study provide the rationale for the preventive use of statins in earlier stages of chronic kidney disease, a concept supported by previous studies 30,31) .…”

Section: Discussionmentioning

confidence: 99%

Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis

Kirmizis

Papagianni

Dogrammatzi

et al. 2010

JAT

View full text Add to dashboard Cite

Efstathios Alexopoulos has passed awayAim: We investigated the effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in hyperlipidemic end-stage renal disease patients on chronic hemodialysis (HD). Methods: In 25 hyperlipidemic HD patients who received 10 mg of simvastatin for 6 months and another 25 controls, the extended lipid profile and serum hsIL-6, MCP-1, sICAM-1, sVCAM-1, and sE-selectin, plasma oxLDL, and serum sFas and sFasL levels were determined at baseline, 3 months and 6 months. In 18 patients of the simvastatin group, the expression of CD14, CD16, CD62L and CD64 on monocyfes was determined with flow cytometry. Result: Simvastatin treatment resulted in significant reductions in serum lipid levels at 3 months and beyond, compared to at baseline. Moreover, at 6 months, simvastatin caused a significant reduction in CRP ( p 0.001), which correlated to the decrease in total and LDL cholesterol levels, as well as a significant reduction in IL-6 ( p 0.001), sICAM-1 ( p 0.001), sVCAM-1 ( p 0.001), oxLDL ( p 0.001), sFas ( p 0.02) and CD14 expression ( p 0.001), compared to baseline values. No significant changes in the controls were noticed during the study. Conclusion: In conclusion, in hyperlipidemic HD patients, simvastatin treatment resulted in a significant reduction in markers of endothelial dysfunction, inflammation, oxidative stress, endothelial cell apoptosis and peripheral blood monocyte stimulation. The reduction in CRP appears to be related to the lipid-lowering effects of simvastatin.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis

Kirmizis

Papagianni

Dogrammatzi

et al. 2010

JAT

View full text Add to dashboard Cite

show abstract

“…Interestingly, subgroup analysis of JUPITER trial showed that rosuvastatin decreased cardiovascular event rates as well as overall mortality in patients with moderate CKD even in the absence of hyperlipidemia (LDL < 130). However, this study originally excluded patients with diabetes and advanced CKD [38] . Other meta-analyses of trials (randomized trials in CKD population plus sub-group analysis of trials of general population) have persistently shown the beneficial effect of statins [39][40][41] .…”

Section: Ckd Patients On Dialysismentioning

confidence: 99%

Lipid abnormalities in kidney disease and management strategies

Pandya

Rao

Chaudhary

2015

WJN

View full text Add to dashboard Cite

lipoprotein and low/dysfunctional low high-density) represents one of the modifiable risk factors. Renal failure patients have unique lipid abnormalities which not only have complex role in pathogenesis of CVD but also cause relative resistance to usual interventions. Most of the randomized trials have been in hemodialysis population and data from CKD non-dialysis, peritoneal dialysis and renal transplant populations is extremely limited. Compared to general population, evidence of mortality benefit of lipid lowering medications in CKD population is scarce. Future research should be directed towards establishing long term benefits and side effects of lipid lowering medications, through randomized trials, in CKD population. Core tip: Burden of cardiovascular disease and dyslipidemia continues to be high among patients with kidney diseases. Our review includes unique lipid abnormalities specifically affecting patients with kidney diseases. We have included comprehensive review of the latest evidence of the dyslipidemia treatment for each subgroup [i.e. , chronic kidney disease (CKD) not on dialysis, CKD on dialysis and Kidney transplant recipients] and current guidelines from Kidney Diseases: Improving Global Outcomes. AbstractPatients with kidney diseases continue to experience significant cardiovascular disease (CVD) morbidity and mortality. Although there are many important risk factors playing a role in the pathogenesis of CVD in chronic kidney disease (CKD) patients, dyslipidemia (elevated triglycerides, elevated oxidized low-density MINIREVIEWS 83February 6, 2015|Volume 4|Issue 1|

show abstract

“…This probably contributes to the inconsistent relationship in studies between cholesterol-lowering therapy and cardiovascular outcome in chronic kidney disease. [32][33][34][35][36][37][38][39][40] In a more recent meta-analysis, statin therapy reduced the risk of first major vascular event by 21% (RR 0.79, 95% CI 0.77-0.81) per mmol/L reduction in LDL cholesterol. Smaller relative effects on major vascular events, major coronary events and vascular mortality were observed as GFR declined.…”

Section: Articlementioning

confidence: 99%

Lipid lowering in renal disease

Kennard

Singer

2017

Aust Prescr

View full text Add to dashboard Cite

Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein

Abstract: Rosuvastatin reduces first cardiovascular events and all-cause mortality among men and women with LDL-C <130 mg/dl, elevated hsCRP, and concomitant evidence of moderate CKD. (JUPITER-Crestor 20 mg Versus Placebo in Prevention of Cardiovascular [CV] Events; NCT00239681).

Cited by 184 publications

References 18 publications

Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis

Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis

Lipid abnormalities in kidney disease and management strategies

Lipid lowering in renal disease

Contact Info

Product

Resources

About